TELA Bio 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- TELA Bio reported 3rd quarter 2026 revenue of $19 million, down 8% compared to the 3rd quarter of 2025; U.S. revenue was $15.4 million and European revenue was $3.6 million.
- U.S. hernia revenue increased slightly sequentially, with U.S. hernia volume growing both year-over-year and sequentially; U.S. hernia volume also grew year-over-year.
- Ovitex PRS revenue was down 20% year-over-year and 6% sequentially, while European revenue grew 18% year-over-year.
- LiquiFix delivered its strongest performance to date, setting a new quarterly sales record, and its customer base expanded 60% year-to-date.
- Gross profit was $12.3 million, or 64.9% of revenue, compared to $14 million, or 67.5% of revenue, in the same period of '25; excluding a $1.1 million noncash charge, gross margin would have been 71%.
- Total operating expenses excluding other expenses were $17.6 million, down 17.8% from $21.4 million in the 3rd quarter of 2025; loss from operations was $7.3 million, a $300,000 improvement compared to 2025.
- Adjusted EBITDA loss was $3.4 million, an improvement of 40% year-over-year and 56% sequentially; TELA Bio ended the quarter with $22.7 million in cash and cash equivalents.
- Perceptive agreed to suspend minimum revenue covenant testing for the quarters ending September 30th and December 31st, 2026; the consent applies specifically to the minimum revenue covenant.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the TELA Bio third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. Following the prepared remarks, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Louisa Smith.
Thank you, operator, and good afternoon, everyone. Earlier today, TELA Bio released financial results for the third quarter ended September 30, 2026. A copy of the press release is available on the company's website. Joining me on today's call are Heather Getz, Chief Executive Officer, Jeff Blizard, President, and Jim Hagen, Senior Vice President of Strategic Commercial Operations and Marketing. Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including without limitation, the company's quarterly reports on Form 10-Q, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements.
These factors may include, without limitation, statements regarding product development, pipeline opportunities, sales and marketing strategies, and the impact of various additional risk factors as identified in our regulatory filings. Heather will begin with the Q3 results and the changes made to strengthen TELA Bio. Jeff will discuss the commercial performance, and then Heather will finish with review of the financial results in more detail before we take your questions. With that, I'll now turn the call over to Heather.
Good afternoon, everyone, and thank you for joining us. Last week marked my 90th day as CEO of TELA Bio, and I want to use this time not just to walk through our Q3 results, but to share what I've learned, what's already in the process of being changed, and where we're headed. When I joined in August, I made a commitment to our board, our employees, and all of you that I would listen first, but act swiftly to stabilize the company and extend our runway. Over these past three months, I have done just that. I've met with surgeons, investors, and employees across the organization. Three things became clear. First, we believe our core product portfolio is best in class at providing both value and performance, and is supported by robust clinical data, even more than I originally appreciated.
I will be discussing today additional evidence of OviTex's outstanding clinical profile, which was issued recently. Second, our capital allocation needed to be much more focused. We have been spreading investments across too many initiatives and too quickly without clear prioritization. Third, when we adjusted our go-to-market strategy late last year, we created some gaps that also need to be addressed. The good news is that we have already made meaningful progress on addressing these items, as you will hear today. I will start with the $17 million cost reduction plan commenced on September 1st. The program was intended to preserve capital while maintaining investment in our core growth priorities, as well as product innovation. We intend to translate the lower cost structure into reduced cash consumption as we improve commercial execution.
Second, on October 5th, NASDAQ notified us that we had regained compliance with its minimum bid price requirement, and TELA Bio will remain listed on the NASDAQ Global Market under the symbol TELA. Importantly, as disclosed following our October 8th special meeting, we do not intend to implement a reverse stock split at this time, but have the option for 12 months if so needed. Third, we implemented an adjusted go-to-market strategy that centers our commercial resources on selling the whole bag with a focus on winning complex, higher ASP procedures, as well as targeted selling in other segments that leverage access and opportunity. To do this, we aligned all of our resources that touch the customer, including medical affairs, strategic contracting, and sales operation. We enhanced field training of both clinical and sales processes, and we updated our sales incentive structure to reward both retention and growth.
While I believe we will see sequential improvement in Q4, this is not a one-quarter fix. It is a multi-pronged, multi-quarter process. I am proud of how the team navigated the third quarter, selling against the continued practice of anti-competitive contracting and bundling in hospitals, overcoming the disruption from the organizational realignment, as well as a challenging market dynamic in which many hospitals and other medical device companies reported that elective procedures were down. Despite these headwinds, we finished Q3 with $19 million in revenue. We delivered sequential revenue and unit growth in the U.S. hernia portfolio, year-over-year volume growth in the U.S. hernia portfolio, and continued year-over-year growth in Europe. These results are encouraging signs of our portfolio strength and our team's commitment.
We also recognized that PRS remains below where it needs to be, and we believe with our recently fine-tuned sales strategy, we will return to previously strong adoption rates in the coming quarters. To be clear, there is no issue with the product, but changes need to be made on how we are addressing the market. Jeff will provide specific details in his commentary about our plans to grow PRS sales. Clinically, we continue to validate the strength of our portfolio with four new peer-reviewed publications and podium presentations on both OviTex and OviTex PRS, demonstrating favorable outcomes compared to gold standard synthetic and biologic alternatives. One was the OviTex meta-analysis authored by three internationally respected KOLs and published in Hernia.
These results demonstrated significantly reduced ventral hernia recurrence rates and comparable safety outcomes with OviTex compared to traditional biologic and synthetic mesh, despite being used in patients with increased risk factors and comorbidities. Another was the publication of our largest PRS study to date that has been accepted for publication in the Plastic and Reconstructive Surgery Journal. This study demonstrates no statistical differences in major infections or operative complications while showing lower odds of seroma formation. I also want to recognize our engineering, quality, and regulatory teams for the FDA 510(k) clearance of the Liora Monofilament Scaffold. Liora is a fully resorbable surgical mesh for soft tissue reinforcement and our first implant fully developed in our Malvern clean room. Our ability to develop and produce a product in-house creates a foundation for greater ownership of the path from product design through manufacturing.
We are proud of this achievement and the capabilities it represents. We are taking a disciplined approach to the next steps with Liora. We will provide you with an update to the commercial plan in early 2027. As you have just heard, we have made significant operational progress across the organization in a relatively short period of time. Going forward, our strategy depends on disciplined execution. We are doubling down on our core products and selling our whole bag in areas where we have opportunity while continuing to add access at the GPO, IDN, and hospital level. Every dollar of capital needs to be allocated to where we will see the highest ROI. Now, I'll turn the call over to Jeff to discuss our commercial results in more detail.
Thank you. As Heather just highlighted, our third quarter results demonstrate meaningful progress and positive momentum across our global commercial organization. At $19 million in total sales, the U.S. revenue was $15.4 million, while European revenue ended at $3.6 million. Breaking down the $15.4 million in the third quarter, our U.S. hernia revenue was up slightly sequentially, while volume grew both year-over-year and sequentially. LIQUIFIX also delivered its strongest performance to date, setting a new TELA Bio quarterly sales record, with its customer base expanding 60% year-to-date. As discussed in previous calls, a gap has been created between unit and revenue growth as continued adoption in minimally invasive and robotic hernia repair has shifted demand towards smaller product sizes. In Q4, we expect this gap to continue to narrow as year-over-year comparisons stabilize the product mix.
While we do not anticipate immediate convergence, our revenue growth should be more in line with our unit growth. Turning to plastic and reconstructive surgery, we were able to slow the decline and refocus and retrain the sales team. OviTex PRS revenue was down 20% year-over-year and 6% sequentially. It is important to note that the decline in PRS revenue has been concentrated in a limited number of markets rather than broadly across the organization. In 2026, in addition to some turnover, we had several key surgeons experience personal or professional circumstances forcing them to step away from their practices, which adversely affected procedural volumes. We are supporting a renewed focus on PRS with enhanced product and procedural training alongside expanded medical affairs capabilities to provide deeper clinical and educational support to both our sales teams and surgical customers.
Collectively, these actions are designed to strengthen commercial effectiveness, deepen surgeon engagement, and rebuild momentum in this strategically important part of our business. Given the longer sales cycle in PRS and the more concentrated surgeon community, the progress we have made in several high-volume centers have not yet offset the declines. Shifting to our international business, in Europe, we have maintained strong momentum, delivering double-digit year-over-year growth at 18%. This year-over-year growth was driven by higher value complex cases, particularly in the U.K. In late September, we hosted 120 European surgeons in Madrid for a two-day educational event entitled Advancing Reconstruction. This program brought together several multiple surgical specialties to exchange clinical experiences, share best practices, and explore innovative approaches to improving patient outcomes, all challenging the notion that hernias are a chronic disease.
Innovations in surgical techniques and OviTex products provide surgeons with a greater opportunity to achieve a successful outcome during this initial procedure. Ultimately, the goal is to deliver durable repair, minimize the risk for recurrence, and reduce the need for subsequent interventions. We believe initiatives like these strengthen our global surgical community and support long-term portfolio growth. I would now like to touch on our initiatives in strategic contracting. While we continue to face market access barriers from large competitors, we are not sitting idle. Our field is making progress in developing physician champions, and our contracting team is complementing these efforts in establishing OviTex agreements site by site. While this process takes longer, these practices are necessary to get OviTex use within these hospitals and their health systems, given the contracting environment in the U.S. In parallel, TELA will continue to pursue a national agreement to broaden access and simplify contracting.
The focus remains on translating access into hospital approvals, physician adoption, and sustained utilization. As I close, I want to emphasize the most important takeaway from Q3, the resilience and execution of our commercial team. In Q3, we constructed a data-driven plan that built around our top markets, strategically positioned our team in the areas with the greatest opportunity to win. By aligning territories with contract access, surgeon partnerships, and high-potential programs, we have concentrated our talent to where we have the clearest path for revenue growth. This disciplined approach ensures that our strongest commercial resources are deployed where we have access, relationships, and opportunity, all while preserving continuity across key accounts. In the midst of these changes to our organization, we delivered sequential U.S. hernia growth that accelerated post-realignment, achieved a record quarter for LIQUIFIX, and posted another quarter of double-digit European growth.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
